Mallinckrodt price target raised to $95 from $85 at Jefferies Jefferies raised its price target for Mallinckrodt (MNK) shares to $95 and added the stock to its Franchise Picks list. The firm upped its estimates to reflect the Questcor (QCOR) acquisition and higher generic pricing. Jefferies thinks Mallinckrodt is well positioned to be either a buyer or a seller following the close of Questcor deal and it keeps a Buy rating on the stock.
News For MNK;QCOR From The Last 14 Days
Check below for free stories on MNK;QCOR the last two weeks.
Mallinckrodt announces MNK-155 Phase 3 efficacy trial met primary endpoint Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014 on September 2-6. In addition to the Phase 3 study, Mallinckrodt will present data at PAINWeek from several other MNK-155 trials, including the pharmacokinetics, safety and subjective effects of abuse-related characteristics.